

## Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion

by Constantine S. Tam, Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, David Simpson, Mazyar Shadman, Peter S. Ganly, Luca Laurenti, Stephen Opat, Monica Tani, Hanna Ciepluch, Emma Verner, Martin Šimkovič, Anders Österborg, Marek Trněný, Alessandra Tedeschi, Jason C. Paik, Sowmya B. Kuwahara, Shibao Feng, Vanitha Ramakrishnan, Aileen Cohen, Jane Huang, Peter Hillmen, and Jennifer R. Brown

Haematologica 2020 [Epub ahead of print]

*Citation: Constantine S. Tam, Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, David Simpson, Mazyar Shadman, Peter S. Ganly, Luca Laurenti, Stephen Opat, Monica Tani, Hanna Ciepluch, Emma Verner, Martin Šimkovič, Anders Österborg, Marek Trněný, Alessandra Tedeschi, Jason C. Paik, Sowmya B. Kuwahara, Shibao Feng, Vanitha Ramakrishnan, Aileen Cohen, Jane Huang, Peter Hillmen, and Jennifer R. Brown. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.*

*Haematologica. 2020; 105:xxx*

*doi:10.3324/haematol.2020.259432*

### *Publisher's Disclaimer.*

*E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.*

**Title:** Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion

**Author Names:**

Constantine S. Tam<sup>1,2,3,4</sup>, Tadeusz Robak<sup>5</sup>, Paolo Ghia<sup>6</sup>, Brad S. Kahl<sup>7</sup>, Patricia Walker<sup>8</sup>, Wojciech Janowski<sup>9</sup>, David Simpson<sup>10,11</sup>, Mazyar Shadman<sup>12,13</sup>, Peter S. Ganly<sup>14</sup>, Luca Laurenti<sup>15</sup>, Stephen Opat<sup>16,17</sup>, Monica Tani<sup>18</sup>, Hanna Ciepluch<sup>19</sup>, Emma Verner<sup>20,21</sup>, Martin Šimkovič<sup>22,23</sup>, Anders Österborg<sup>24,25</sup>, Marek Trněný<sup>26</sup>, Alessandra Tedeschi<sup>27</sup>, Jason C. Paik<sup>11</sup>, Sowmya B. Kuwahara<sup>11</sup>, Shibo Feng<sup>11</sup>, Vanitha Ramakrishnan<sup>11</sup>, Aileen Cohen<sup>11</sup>, Jane Huang<sup>11</sup>, Peter Hillmen<sup>28</sup>, and Jennifer R. Brown<sup>29</sup>

**Author Affiliations:**

<sup>1</sup>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

<sup>2</sup>University of Melbourne, Parkville, Victoria, Australia

<sup>3</sup>Royal Melbourne Hospital, Parkville, Victoria, Australia

<sup>4</sup>St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia

<sup>5</sup>Medical University of Lodz, Lodz, Poland

<sup>6</sup>Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

<sup>7</sup>Washington University School of Medicine, St Louis, MO, USA

<sup>8</sup>Peninsula Private Hospital, Frankston, Victoria, Australia

<sup>9</sup>Calvary Mater Newcastle, Waratah, NSW, Australia

<sup>10</sup>North Shore Hospital, Auckland, New Zealand

<sup>11</sup>BeiGene USA, Inc., San Mateo, CA, USA

<sup>12</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA

<sup>13</sup>Department of Medicine, University of Washington, Seattle, WA, USA

<sup>14</sup>Department of Haematology, Christchurch Hospital, Christchurch, New Zealand

<sup>15</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

<sup>16</sup>Monash Health, Clayton, Victoria, Australia

<sup>17</sup>Monash University, Clayton, Victoria, Australia

<sup>18</sup>Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy

<sup>19</sup>Copernicus Wojewódzkie Centrum Onkologii, Gdąnsk, Poland

<sup>20</sup>Concord Repatriation General Hospital, Concord, NSW, Australia

<sup>21</sup>University of Sydney, Concord, NSW, Australia

<sup>22</sup>Fourth Department of Internal Medicine - Hematology, University Hospital, Hradec Kralove, Czech Republic

<sup>23</sup>Faculty of Medicine, Charles University, Prague, Czech Republic

<sup>24</sup>Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

<sup>25</sup>Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

<sup>26</sup>First Department of Medicine, First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic

<sup>27</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

<sup>28</sup>St James's University Hospital, Leeds, United Kingdom

<sup>29</sup>Dana-Farber Cancer Institute, Boston, MA, USA

**Corresponding Author:**

Constantine S. Tam, Peter MacCallum Cancer Centre, 305 Grattan St, Parkville, VIC 3050, Australia; e-mail: constantine.tam@petermac.org.

**Short Title for the Running Head:** Zanubrutinib in treatment naïve del(17p) CLL/SLL

**Formatting:**

- Abstract word count: 250
- Text word count: 3530
- Number of figures and tables: 5 + *7 supplemental*
- Number of references: 45

**Trial Registration:** Clinicaltrials.gov identifier: NCT03336333

**Abstract** (250 words)

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-generation Bruton tyrosine kinase inhibitor. We evaluated the safety and efficacy of zanubrutinib 160 mg twice daily in treatment-naïve patients with del(17p) disease enrolled in a dedicated, nonrandomized cohort (Arm C) of the phase 3 SEQUOIA trial. A total of 109 patients (median age, 70 years; range, 42 – 86) with centrally confirmed del(17p) were enrolled and treated. After a median of 18.2 months (range, 5.0 – 26.3), seven patients had discontinued study treatment due to progressive disease, four due to an adverse event, and one due to withdrawal of consent. The overall response rate was 94.5% with 3.7% of patients achieving complete response with or without incomplete hematologic recovery. The estimated 18-month progression-free survival rate was 88.6% (95% CI, 79.0 – 94.0) and the estimated 18-month overall survival rate was 95.1% (95% CI, 88.4 – 98.0). Most common all-grade adverse events included contusion (20.2%), upper respiratory tract infection (19.3%), neutropenia/neutrophil count decreased (17.4%), and diarrhea (16.5%). Grade  $\geq$  3 adverse events were reported in 53 patients (48.6%), most commonly neutropenia (12.9%) and pneumonia (3.7%). An adverse event of atrial fibrillation was reported in three patients (2.8%). Zanubrutinib was active and well tolerated in this large, prospectively enrolled treatment cohort of previously untreated patients with del(17p) chronic lymphocytic leukemia/small lymphocytic lymphoma. This trial was registered at ClinicalTrials.gov as #NCT03336333.

## Introduction

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have historically been treated with combination chemotherapy and immunotherapy with success; however, many patients do not have sustained responses in part due to genomic aberrations that impair responsiveness to therapy. One aberration found in patients with CLL/SLL is the deletion of chromosome 17p13.1 [del(17p)]; these patients have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy, with reduced rates of overall survival (OS) and worse clinical outcomes.<sup>1,2</sup> del(17p) results in the mono or biallelic loss of the *TP53* gene, which encodes the tumor suppressor p53, a multifunctional transcription factor important for cellular response to DNA damage, including cell cycle arrest and apoptosis.<sup>3</sup> Most patients with del(17p) also have mutation of the other *TP53* allele and therefore lack wild-type *TP53*, leading to genomic instability and reduced responsiveness to cytotoxic chemotherapy.<sup>2</sup> The incidence of del(17p) is approximately 5% to 8% of patients with CLL at diagnosis and increases with each relapse.<sup>4,5</sup>

Novel targeted therapies are therefore the preferred treatment modality for previously untreated patients whose disease bears the del(17p) mutation.<sup>6,7</sup> Several new agents are approved by the US Food and Drug Administration and European Medicines Agency (EMA) for adult patients with CLL/SLL regardless of del(17p) status, including the BTK inhibitors ibrutinib and acalabrutinib. In the RESONATE study of ibrutinib vs ofatumumab in patients with relapsed or refractory (R/R) CLL/SLL,<sup>8</sup> 89% of ibrutinib-treated patients with del(17p) achieved an objective response with long term follow-up.<sup>9</sup> Similar results were observed in the single-arm RESONATE-17 study in R/R CLL<sup>10</sup> in which 83% of patients achieved an objective response; the 24-month progression-free survival (PFS) was 63%. Acalabrutinib, a second-

generation BTK inhibitor, has been approved recently for treatment-naïve (TN) patients with CLL/SLL regardless of del(17p) status based on results from the ELEVATE TN study.<sup>11,12</sup> Notably, of the patients with del(17p) in that study, only 16 were assigned to the single-agent acalabrutinib arm.

Other small molecule inhibitors approved in patients with CLL/SLL and del(17p) include the Bcl-2 inhibitor venetoclax<sup>13</sup> and the phosphatidylinositide-3-kinase (PI3K)-delta inhibitor idelalisib.<sup>14</sup> Stilgenbauer and colleagues reported the results of venetoclax treatment in 158 mostly R/R del(17p) patients,<sup>15</sup> including a 77% overall response rate (ORR) and an estimated 24-month PFS of 50%. Notably, only five patients in this study were TN. In the CLL14 trial which compared venetoclax and obinutuzumab to chlorambucil and obinutuzumab in TN CLL, 17 patients assigned to the venetoclax arm had del(17p).<sup>16</sup> Similarly, studies supporting the approval of idelalisib together with rituximab in the frontline setting by the EMA included few TN CLL/SLL patients with del(17p).<sup>17,18</sup> Collectively, only limited data are available for novel targeted therapies for previously untreated patients with del(17p) CLL/SLL, and no large multicenter studies have systematically examined this specific population.

Zanubrutinib (BGB-3111) is a next-generation BTK inhibitor with favorable oral bioavailability and high specificity for BTK, exhibiting comparatively lower off-target activity than ibrutinib for structurally related kinases such as epidermal growth factor receptor (EGFR), interleukin-2 inducible kinase (ITK), and Src family kinases.<sup>19</sup> The safety, pharmacokinetics, pharmacodynamics, and preliminary activity of zanubrutinib were investigated in a phase 1/2 study of patients with multiple B-cell malignancies in which high level, sustained BTK occupancy was noted in both peripheral blood and lymph nodes at the recommended phase 2 dose of 160 mg twice daily (bid).<sup>20</sup> Encouraging activity was observed in a cohort of 78 patients

with both TN and R/R CLL/SLL, including in a subset of 16 patients with del(17p) or *TP53* mutation who achieved a 100% ORR.<sup>20</sup> Activity of zanubrutinib was also observed in a separate phase 2 trial of 91 R/R CLL/SLL patients in China, including in a subset of 17 patients with del(17p) who achieved a 88.2% ORR.<sup>21</sup> Zanubrutinib has recently received accelerated approval in the United States for adult patients with mantle cell lymphoma who have received at least one prior therapy<sup>22</sup> and is currently undergoing further clinical testing in several prospective, multicenter, randomized phase 3 trials in CLL/SLL.

The SEQUOIA trial (NCT03336333) is an open-label, multicenter, randomized phase 3 study of TN patients with CLL/SLL. Patients without centrally confirmed del(17p) were randomized to receive either zanubrutinib 160 mg bid until unacceptable toxicity or disease progression (PD), or six cycles of rituximab and bendamustine. Considering the poor outcomes associated with any standard chemoimmunotherapy regimen in patients with del(17p), those with centrally confirmed del(17p) during screening for SEQUOIA were not randomized but assigned to single-agent zanubrutinib in a separate cohort (Arm C). This is the first report of the safety and efficacy results in this high-risk del(17p) patient cohort.

## **Methods** (500/500 words)

### **Study design and population**

Eligible patients had confirmed CLL/SLL requiring treatment per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) definition.<sup>23</sup> TN adults were eligible if either aged  $\geq$  65 years or unsuitable for treatment with fludarabine, cyclophosphamide, and rituximab (FCR) and an Eastern Cooperative Oncology Group (ECOG) performance status  $\leq$  2.<sup>24</sup> Centrally confirmed del(17p) by fluorescence in situ hybridization with  $>$  7% aberrant nuclei present was

required. Patients had adequate end-organ function, including absolute neutrophil count (ANC)  $\geq 1000/\text{mm}^3$  and platelet count  $\geq 75,000/\text{mm}^3$ . For patients with bone marrow involvement, ANC  $\geq 750/\text{mm}^3$  and platelet count  $\geq 50,000/\text{mm}^3$  were allowed. Patients with history of atrial fibrillation and/or long-term anticoagulation, or those requiring moderate or strong CYP3A inhibitors, could enroll.<sup>25</sup> All Arm C patients were assigned to receive zanubrutinib (160 mg bid) until intolerance or PD.

This study was conducted according to principles of the Declaration of Helsinki and the International Conference on Harmonization guidelines for Good Clinical Practice and approved by the Institutional Review Board/Ethics Committee at each participating site. All patients provided written informed consent. This study adhered to CONSORT-10 guidelines for reporting.<sup>26</sup>

### **Objectives and assessments**

Key objectives for Arm C included assessments of ORR, PFS, duration of response (DOR), and safety (frequency and severity of all treatment-emergent adverse events [AEs]). ORR was assessed per modified iwCLL criteria for CLL<sup>23,27</sup> and per Lugano criteria for SLL.<sup>28</sup> Measurable disease, defined as  $\geq 1$  lymph node  $> 1.5$  cm in the longest diameter and measurable in two perpendicular diameters, was assessed by computed tomography/magnetic resonance imaging. Response assessments were performed every 12 weeks after the first dose day for 96 weeks, then every 24 weeks until PD or initiation of new, nonprotocol therapy, whichever came first. Patients underwent bone marrow examination at baseline and for confirmation of complete response (CR), or CR with incomplete hematologic recovery (CRi), or if PD was suspected due to cytopenia.



All treatment-emergent AEs, including AEs of interest (AEI) based on the known toxicity profile for BTK inhibitors occurring on or after day 1 until 30 days after treatment discontinuation were summarized. AEs were categorized in accordance with predefined MedDRA search criteria (**Supplemental Table 1**). AE severity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03 and the Grading Scale for Hematologic Toxicity in CLL Studies.<sup>23</sup> Biomarkers were assessed at baseline and optionally at progression.

## **Statistical analyses**

Primary efficacy and safety analyses included all patients with centrally confirmed del(17p) CLL/SLL receiving  $\geq 1$  dose of zanubrutinib. ORR was summarized as percentage of responders (CR, CRi, nodular partial response [nPR], partial response [PR], or PR with lymphocytosis [PR-L]) with corresponding 95% CI. An evaluation of ORR in subgroups defined by key demographic and baseline disease characteristics was conducted and summarized in a forest plot. DOR was defined as time from first response until PD or death due to any cause. PFS was measured from time of first dose to PD or death due to any cause. Median DOR, PFS, and event-free survival rates were estimated using Kaplan-Meier methodology with corresponding 95% CIs.

## **Results**

### **Patient characteristics and disposition**

Between February 3, 2018 and February 20, 2019, 109 patients with centrally confirmed del(17p) CLL/SLL were enrolled from 59 sites in 13 countries (**Supplemental Table 2**) and

received  $\geq 1$  dose of zanubrutinib. Two additional patients without del(17p) were assigned in error to this study arm and are not included in the analysis. At the data cutoff date of April 15, 2020, the median duration of study follow-up was 18.2 months (range, 5.0 – 26.3). Median age at study entry was 70.0 years (range, 42 – 86); the majority of patients presented with CLL (90.8%). Reported reasons for treatment per iwCLL criteria in order of frequency included progressive marrow failure (41.3%); massive, progressive, or symptomatic lymphadenopathy (41.3%); significant fatigue (33.0%); night sweats (32.1%); progressive lymphocytosis with increase of  $> 50\%$  over two months or doubling time of  $< 6$  months (28.4%); massive, progressive, or symptomatic splenomegaly (23.9%); and unintentional weight loss (14.7%). More than one reason for treatment may have been given, with a median of two reasons given for each patient. Many patients had other high-risk disease characteristics, including 40 patients with CLL who presented as Binet stage C (40.4%), 42 patients with bulky disease  $\geq 5$  cm (38.5%), 78 patients with elevated  $\beta 2$ -microglobulin (78.8% of 99 patients with available data), and 67 patients with an unmutated immunoglobulin heavy chain variable (IGHV) locus (65.0% of 103 patients with sufficient RNA for testing). Furthermore, 32 (37.2%) of 86 patients with sufficient metaphases available for analysis had at least 3 distinct karyotypic abnormalities defined as complex karyotype (**Table 1**).

## **Efficacy**

The ORR was 94.5%, which included three patients (2.8%) with CR, one patient (0.9%) with CRi, 95 (87.2%) with PR, and 4 (3.7%) with PR-L (**Table 2**). Five (4.6%) patients had a best response of stable disease (SD). One patient (0.9%) had PD at the first response assessment. Five (4.6%) patients met clinical CR criteria but did not undergo bone marrow

biopsy. 97 patients (89.0%) remained on treatment at the time of analysis. Nine patients with an initial response (8.3%) progressed on study, four of whom had histologically confirmed Richter transformation. Median time to transformation was 13.7 mo (time to transformation for each patient: 3.9, 13.6, 13.8, and 15.7 mo). Two other patients had new lesions seen on CT with positron emission tomography (PET) avidity for which biopsy could not definitively confirm transformation, while one other patient had accelerated CLL. Seven patients who have progressed have discontinued treatment; two other patients with progression remained on treatment at time of data cutoff. Four patients who progressed have died; two due to progression, one due to an adverse event after progression (acute kidney injury), and one after progression due to septic shock. Four patients (3.7%) discontinued treatment due to AEs, of whom 2 have died (see Safety below), while one patient discontinued treatment after withdrawal of consent and was lost to follow up.

Median PFS and OS were not reached. The estimated 18-month PFS rate was 88.6% (95% CI, 79.0 – 94.0) (**Figure 1A**), while the estimated 18-month OS rate was 95.1% (95% CI, 88.4 – 98.0) (**Figure 1B**). The median time to response was 2.8 months (range, 1.9 – 16.5). The median DOR was not reached; 92.8% of patients had a DOR  $\geq$  12 months (**Figure 1C**). ORR was consistent across all prespecified demographic and baseline disease characteristics (**Figure 2**).

Transient treatment-related lymphocytosis was observed (**Supplemental Figure 1A**), but there was a significant reduction in target lesion size by the first scheduled response assessment, consistent with the short median time to response (**Supplemental Figure 1A**). The peak median change in absolute lymphocyte count (ALC) and time to resolution of lymphocytosis both appeared to be decreased from previous experience with zanubrutinib.<sup>19</sup> In

an exploratory analysis, changes in ALC were compared between patients with mutated and unmutated IGHV locus. Patients with unmutated IGHV showed a slight trend towards less treatment-related lymphocytosis (**Supplemental Figure 1B**), similar to previous reports.<sup>9,29</sup>

Sixty-one patients (56.0%) began the study with at least one cytopenia (**Table 1**), including 43 patients with anemia (39.4%), eight patients with neutropenia (7.3%), and 28 patients with thrombocytopenia (25.7%) (**Supplemental Table 3**). Eleven patients (10.1%) received at least one dose of a granulocyte colony-stimulating factor, while one patient (0.9%) received at least one dose of an erythrocyte-stimulating growth factor. Of those patients with baseline anemia, 86.0% of patients demonstrated sustained improvement in hemoglobin; 75.0% of patients with baseline neutropenia also demonstrated sustained improvement in ANC, and 85.7% of patients with baseline thrombocytopenia demonstrated sustained improvement in platelet count (**Supplemental Table 3**).

In an exploratory post hoc analysis, baseline characteristics and response rate were compared between patients with a percentage of del(17p)-positive nuclei of  $\geq 20\%$  [del(17p) high] vs patients with a percentage of  $> 7\%$  to  $< 20\%$  [del(17p) low] (**Supplemental Table 4**). Patients in the del(17p) high category were observed to have a higher rate of unmutated IGHV (75% vs 56.4% of patients with a resulted test;  $P = 0.0478$ ) and complex karyotype status (56.8% vs 22.4% of patients with sufficient metaphases for analysis;  $P = 0.0011$ ); no other differences in baseline characteristics were observed. Best ORR and estimated 18-month PFS were 98% and 89%, respectively, in the del(17p) high category and 92% and 88%, respectively, in the del(17p) low category.

## Safety

AEs of any grade reported in  $\geq 10\%$  of patients included contusion (20.2%), upper respiratory tract infection (19.3%), neutropenia/neutrophil count decreased (17.4%), diarrhea (16.5%), nausea (14.7%), rash (13.8%), constipation (13.8%), back pain (12.8%), cough (11.9%), arthralgia (11.0%), and fatigue (10.1%) (**Table 3**). Grade  $\geq 3$  events were reported in 53 patients (48.6%), with neutropenia/decreased neutrophil count (12.9%) and pneumonia (3.7%) being the most common. Serious AEs (SAE) were reported in 36.7% of patients, with pneumonia (3.7%) being the most common. AEs led to dose reduction in 6 (5.5%) patients and included thrombocytopenia, diarrhea, gastritis, blood bilirubin increased, arthralgia, myalgia, and headache. All six patients remain on treatment.

Four patients discontinued treatment due to AE; a 77 year old male patient had grade 4 pseudomonal sepsis associated with grade 4 neutropenia and atrial fibrillation who recovered, while another 72 year old male patient had grade 3 melanoma requiring surgery and adjuvant therapy. One grade 5 event was reported in a 84 year old female patient with health-care associated pneumonia diagnosed eight days after the last dose of zanubrutinib which was held for an unrelated procedure. This case was complicated by the development of sepsis which was assessed as related to zanubrutinib. Finally, one grade 5 event was reported in a 72 year old male patient who developed disease progression at the Week 36 response assessment including massive enlargement of intraabdominal lymph nodes associated with hypercalcemia. Prior to discontinuation of study drug, the patient shortly thereafter had renal failure requiring dialysis and subsequently died due to pulmonary edema. No sudden or unknown deaths were reported.

AEIs known to be associated with BTK inhibitors were characterized in greater detail, including grouping of similar AEs by category (**Supplemental Table 1**). AEIs reported in  $\geq$

10% of treated patients included infections (64.2%; 13.8% grade  $\geq$  3), minor bleeding (26.6%), bruising (24.8%; 0% grade  $\geq$  3), neutropenia (18.3%; 13.8% grade  $\geq$  3), diarrhea (15.6%; 0.9% grade  $\geq$  3), nausea (13.8%; 0% grade  $\geq$  3), arthralgia (11.0%; 0% grade  $\geq$  3), fatigue (10.1%; 0.9% grade  $\geq$  3) (**Supplemental Table 5**). The most common infections reported in  $\geq$  5% of patients included upper respiratory tract infection (19.3%), pneumonia (8.3%), nasopharyngitis (7.3%), and urinary tract infection (6.4%); most of these were grade 1 or 2 events. Prophylaxis against opportunistic infections was allowed per local standard of care but not required; no opportunistic infections were reported.

Of other malignancies reported on study, most were dermatological malignancies reported in 10 patients (9.2%). Other than two patients with melanoma, all were basal and squamous cell carcinomas of the skin (grade 1/2) reported from patients in Australia and New Zealand, where skin cancers are frequent, especially in patients with CLL/SLL.<sup>30,31</sup> One patient developed grade 3 melanoma requiring surgery and adjuvant therapy with pembrolizumab leading to discontinuation of zanubrutinib. Five patients (4.6%) reported a non-dermatologic other malignancy. One patient developed localized breast cancer for which axillary lymph node biopsy indicated disease transformation to DLBCL, while one other patient developed lung cancer for which interlobar lymph node biopsy also indicated disease transformation to DLBCL. Three patients reported a transitional cell carcinoma of the bladder or ureter, all of whom underwent resection without known residual disease and remain on study drug treatment.

The usage of therapeutic anticoagulation was not restricted on this study; 20 patients (18.3%) were reported to have taken a therapeutic anticoagulant including warfarin, direct-acting oral anticoagulants, and heparins during the study, while 27 patients (24.8%) were

reported to have taken an oral platelet aggregation inhibitor, including aspirin, during the study. Bleeding of any type was reported in 47.7% of patients (4.6% grade  $\geq$  3). Major bleeding events were defined as any bleeding event with grade  $\geq$  3, any SAE, or any bleed affecting the central nervous system (CNS); these occurred in six patients (5.4%). A description of each event, including any confounding factors, is presented in **Supplemental Table 6**; in two patients, bleeding occurred in the setting of a surgical procedure without dose hold as advised per protocol. All patients continued study treatment after dose interruption. No bleeding events affecting the CNS were reported.

A history of atrial fibrillation or flutter was reported in seven patients (6.4%); four patients (3.7%) entered the study with controlled and hemodynamically stable atrial fibrillation or flutter. An AE of atrial fibrillation or flutter was reported in three patients (2.8%). One grade 2 event was reported in a 71 year old male patient with hypertension and prior history of atrial fibrillation, while a grade 3 event was reported in a 78 year old male patient who was septic from cholecystitis. Both of these events resolved and did not require discontinuation of study treatment. Finally, one grade 4 event was reported in a 77 year old male patient with grade 3 hypertension at baseline, who discontinued treatment due to sepsis secondary to *Pseudomonas*; atrial fibrillation resolved following recovery from sepsis.

## **Discussion**

In this report, we have shown the activity and safety of zanubrutinib in a large non-randomized cohort of treatment-naïve CLL/SLL patients with centrally confirmed del(17p), enrolled as part of the global SEQUOIA trial. As expected, these results compare favorably with those from previous studies of TN patients treated with chemoimmunotherapy, including

the CLL8 trial of FCR.<sup>1,2,32</sup> At the present time, prospective clinical trial data from BTK inhibitor-treated patients with TN del(17p) CLL/SLL are limited. Patients with del(17p) were not eligible for enrollment in RESONATE-2<sup>33</sup> and the ECOG-E1912<sup>34</sup> trials evaluating ibrutinib in the TN setting. The Alliance A041702 study, comparing chemotherapy, ibrutinib, or ibrutinib and rituximab in older patients with TN CLL/SLL, did allow patients with del(17p) to enroll; of these, 6% had del(17p), and only nine patients were assigned to receive ibrutinib alone.<sup>35</sup> Two studies examining combinations of novel targeted therapies with anti-CD20 antibodies also enrolled a small number of TN patients with del(17p), including the iLLUMINATE study, where 14 patients with del(17p) received combination ibrutinib and obinutuzumab.<sup>36</sup> In a single-center, phase 2 study, single-agent ibrutinib was evaluated in 35 patients with TN CLL; notably, this population was selected based on cytogenetics or *TP53* sequencing and allowed younger and/or fit patients, leading to enrollment of a population with a median age of 62.<sup>37,38</sup> At a median follow-up time of 15 months, ORR was reported as 97%, including 12% CR, 70% PR, and 15% PR-L.

The ORR with zanubrutinib observed in the present study appears at least comparable with the reported ibrutinib experience. Median time to response essentially was defined by the first scheduled response assessment (**Figure 1C**), consistent with reduction in target lesion size (**Supplemental Figure 1A**) and resolution of cytopenias (**Supplemental Table 3**). Consistent with previous studies of other BTK inhibitors,<sup>12,32,37</sup> CRs were uncommon with short follow-up; longer follow-up will be needed to more precisely define the CR rate. Response rates appear to be similarly high regardless of coincident risk factors, including IGHV mutational status and complex karyotype status, though the low number of non-responders may limit the ability to detect meaningful differences between subgroups.



In the UK LRF CLL4 trial, del(17p) in > 20% of nuclei was found to be independently associated with shorter PFS in patients treated with chemoimmunotherapy.<sup>39,40</sup> As expected, patients with a higher burden of del(17p) were associated with a higher rate of poor prognostic factors such as unmutated IGHV status and complex karyotype. When examining ORR and progression events in the current study, ORR appeared to be similar in patients without and with del(17p) in  $\geq$  20% of nuclei (**Supplemental Table 4**), suggesting that zanubrutinib has preserved activity in high-risk patients with enrichment of malignant cells for del(17p). This is comparable to the activity seen in the RESONATE-17 trial of R/R patients with del(17p) treated with ibrutinib.<sup>10</sup>

Ten patients progressed on study. In addition to presence of del(17p), seven patients who progressed had an unmutated IGHV locus. Karyotype analysis was available for eight patients who had progressed, of whom two had complex karyotype (number of abnormalities: 5 and 6). Four patients had histologically confirmed transformation to aggressive lymphoma, while two patients had suspected transformation. The present results compare favorably to those reported with chemoimmunotherapy, where 23% of patients with del(17p) treated in the first line experienced disease transformation, with a median time to transformation of 12 months.<sup>41</sup> In the RESONATE-17 trial of R/R CLL patients, 44% of progression events were due to transformation, most within the first six months of treatment.<sup>10</sup> Similarly, both early progression events in the TN del(17p) or *TP53* populations treated with ibrutinib, as reported by Farooqi and colleagues, occurred due to Richter transformation.<sup>37</sup> These data are in line with the known association of del(17p) and transformation to aggressive lymphomas.<sup>42</sup> Long term outcomes for patients with del(17p) treated with ibrutinib were reported by Ahn and colleagues,<sup>38</sup> showing an approximate 5 year PFS of 75%. Further follow-up will be required to

demonstrate the durability of responses to zanubrutinib. Additional analyses, including correlation of response and progression with concurrent genomic abnormalities and other genetic mutations (eg, *TP53*, *NOTCH1*, *BTK*, and *PLCG2* mutations), both at baseline and at the time of progression, are currently in progress.

The clinically meaningful activity noted in this patient series appears to be associated with a favorable toxicity profile and is consistent with that reported in other studies of zanubrutinib to date.<sup>20,43</sup> Despite enrolling a more elderly and comorbid population and allowing for therapeutic anticoagulation on study, the incidence of grade  $\geq 3$  AEs or SAEs leading to major bleeding was 5.6% with no CNS events reported, and all patients able to continue study drug after dose interruption. Consistent with its greater selectivity for BTK and less inhibition of kinases such as EGFR, Src, and others, the incidence of grade  $\geq 3$  AEs such as diarrhea, arthralgia, and myalgia were all  $\leq 1\%$ . Importantly, only three patients on this study reported treatment-emergent atrial fibrillation, six patients required ongoing dose reduction, and four patients discontinued zanubrutinib due to an AE. Two phase 3 randomized studies in patients with R/R CLL/SLL<sup>44</sup> and Waldenström macroglobulinemia<sup>45</sup> are ongoing to directly compare the efficacy and safety profiles of ibrutinib and zanubrutinib.

Limitations of this study include the relatively short duration of follow-up and its single-arm design. A retrospective analysis for baseline *TP53* mutations is currently being performed for this study arm and the larger randomized arms. Analogous to other BTK inhibitors, the single-agent activity of zanubrutinib is not expected to induce a deep response with eradication of minimal residual disease (MRD). Several studies have recently reported achievement of undetectable MRD in patients with TN CLL/SLL, including those patients with del(17p), by combining a BTK inhibitor with obinutuzumab or venetoclax.<sup>36,46,47</sup> The SEQUOIA trial is

currently enrolling patients in Arm D, which will evaluate the safety and activity of a combination of zanubrutinib with venetoclax in TN CLL/SLL patients with del(17p). In summary, these results indicate that single-agent zanubrutinib is active and generally well tolerated in this very high-risk population.

## **Acknowledgments**

The authors thank the patients who participated in the study, their supporters, and the investigators and clinical research staff from the study centers.

Medical writing and editorial assistance were provided, under the direction of the authors, by Bio Connections. This work, including medical writing and editorial assistance, was supported by BeiGene USA, Inc. BeiGene was involved in the study design, compilation of data, and statistical analysis.

## **Authorship**

Contribution: Together with BeiGene authors (AC, SF, VR, and JH), CST, PH, TR, PG, BSK, and JRB were responsible for study design, and CST, JRB, JCP, SBK, AC, SF, VR, and JH contributed to data interpretation and analysis. All investigators and their respective research teams reviewed patient records and contributed to data collection; BeiGene authors (JCP, SBK, SF, VR, AC, and JH) confirmed assay validation and data accuracy and compiled data for summation and analysis. CST, JCP, SBK, SF, and VR contributed to the first draft of the manuscript; all authors further contributed to final manuscript writing; CST had final responsibility to submit for publication. All authors had full access to all of the data, carefully reviewed the manuscript, and approved the final version.

## **Conflict-of-interest disclosure**

CST received research funding from Janssen, AbbVie, BeiGene, Pharmacyclics, TG

Therapeutics and AbbVie and served as a consultant for BeiGene, Janssen, Roche, AbbVie and Loxo; TR served as a consultant for and received honoraria and research funding from Gilead; PG served as a consultant for Adaptive, AbbVie, ArQule, BeiGene, Celgene/Juno,

Dynamo, Gilead, Janssen, Sunesis and received research funding from AbbVie, Gilead, Janssen, Novartis, and Sunesis; LL received honoraria from Roche and AbbVie, and served as a consultant for BeiGene, Roche, AbbVie, AstraZeneca, Janssen, and Gilead; BSK served as a consultant for AbbVie, Acerta, AstraZeneca, BeiGene, Janssen and Pharmacyclics; PW is an employee of Alfred Health (public hospital) and Peninsula Health (public hospital) and received travel funding from Roche; WJ served as a consultant for AstraZeneca and served on advisory boards for Janssen, Celgene, and Amgen; DS is an employee of and has equity ownership in BeiGene, received honoraria from AbbVie, Janssen, and Roche, received research funding from AbbVie, Amgen, Celgene, Roche, MSD, Acerta, Pharmacyclics, Sanofi, and GSK; MS served as a consultant for AbbVie, Genentech, AstraZeneca, Pharmacyclics, Verastem, ADC Therapeutics, Atara Biotherapeutics, Cellectar, and Bristol Myers Squibb, and received research funding from Mustang Bio, Celgene, Pharmacyclics, Gilead and Genentech, TG Therapeutics, BeiGene, AstraZeneca, Sunesis, Acerta Pharma, Atara Biotherapeutics, and Bristol Myers Squibb; PSG has nothing to disclose; LL has nothing to disclose; SO received honoraria from and served as a consultant for AbbVie, Roche, AstraZeneca, Merck, Gilead, Janssen, and Novartis, received research funding from BeiGene, Roche, AstraZeneca, Janssen, Merck, Amgen, and Epizyme, and received travel funding from Roche; MT has nothing to disclose; HC is an employee of Copernicus Wojewódzkie Centrum Onkologii Gdańsk; EV received research funding from Janssen; MŠ served as a consultant for and received travel expenses from AbbVie, Gilead, Janssen-Cilag, and Acerta, and served on an advisory board for AbbVie; AÖ received research funding from BeiGene; MT is an employee of the Charles University General Hospital, served as a consultant for Takeda, Bristol Myers Squibb, Incyte, AbbVie, Amgen, Roche, Gilead Sciences, Janssen, Celgene, MorphoSys,

received honoraria from Janssen, Gilead Sciences, Takeda, Bristol Myers Squibb, Amgen, AbbVie, Roche, MorphoSys, and Incyte; AT served as a consultant for and received honoraria from Janssen-Cilag SpA, AstraZeneca, and AbbVie; JCP, SBK, and SF are employees of and have equity ownership in BeiGene USA; VR is an employee of, has a leadership role and equity ownership in, and received travel funding from BeiGene USA; AC is an employee of, has equity ownership in, and received travel funding from BeiGene USA; JH is an employee of, has a leadership role with, and has equity ownership in BeiGene USA; PH received research funding from AbbVie, Pharmacyclics, Janssen, Gilead, and Roche, received honoraria from AbbVie and Janssen, and served on advisory boards for Acerta, Janssen, and AbbVie; JRB served as a consultant for AbbVie, Acerta, AstraZeneca, BeiGene, Catapult Therapeutics, Dynamo Therapeutics, Genentech/Roche, Gilead, Juno/Celgene, Kite, Loxo, Novartis, Pfizer, Pharmacyclics, Sun, Sunesis, TG Therapeutics, Nextcea and Verastem, received research funding from Gilead, Loxo, Sun and Verastem, received honoraria from Janssen and Teva, and served on the data safety monitoring board for Morphosys and Invectys.

## References

1. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. *J Clin Oncol.* 2012;30(26):3209-3216.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet.* 2010;376(9747):1164-1174.
3. Kasthuber ER, Lowe SW. Putting p53 in context. *Cell.* 2017;170(6):1062-1078.
4. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med.* 2000;343(26):1910-1916.
5. Yu L, Kim HT, Kasar S, et al. Survival of del17p CLL depends on genomic complexity and somatic mutation. *Clin Cancer Res.* 2017;23(3):735-745.
6. Aitken MJL, Lee HJ, Post SM. Emerging treatment options for patients with p53-pathway-deficient CLL. *Ther Adv Hematol.* 2019;10:2040620719891356.
7. Brander D, Islam P, Barrientos JC. Tailored treatment strategies for chronic lymphocytic leukemia in a rapidly changing era. *Am Soc Clin Oncol Educ Book.* 2019;39:487-498.
8. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med.* 2014;371(3):213-223.
9. Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. *Leukemia.* 2018;32(1):83-91.
10. O'Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. *Lancet Oncol.* 2016;17(10):1409-1418.
11. Calquence® [package insert]. Gaithersburg, MD: AstraZeneca; November 2019.
12. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. *Lancet.* 2020 ;395(10232):1278-1291.
13. Venclyxto® [summary of product characteristics]. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG; April 2020.
14. Zydelig® [summary of product characteristics]. County Cork, Ireland: Gilead Sciences, Inc.; April 2019.
15. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. *J Clin Oncol.* 2018;36(19):1973-1980.

16. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. *N Engl J Med.* 2019;380(23):2225-2236.
17. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med.* 2014;370(11):997-1007.
18. O'Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. *Blood.* 2015;126(25):2686-2694.
19. Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase. *J Med Chem.* 2019;62(17):7923-7940.
20. Tam CSL, Trotman J, Opat S, et al. Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. *Blood.* 2019;134(11):851-859.
21. Xu W, Yang S, Zhou K, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. *J Hematol Oncol.* 2020;13(1):48.
22. Brukinsa® [package insert]. Beijing, China: BeiGene Co. Ltd.; November 2019.
23. Hallek M, Cheson BD, Catovsky D, et al. iwCLL Guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood.* 2018;131(25):2745-2760.
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol.* 1982;5(6):649-655.
25. Mu S, Tang Z, Novotny W, et al. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. *Cancer Chemother Pharmacol.* 2020;85(2):391-399.
26. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Int Med.* 2010;152:726-732.
27. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. *J Clin Oncol.* 2012;30(23):2820-2822.
28. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *J Clin Oncol.* 2014;32(27):3048-3058.
29. Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. *Leukemia.* 2014;28(11):2188-2196.
30. Hock BD, McIntosh ND, McKenzie JL, et al. Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients. *Intern Med J.* 2016;46(12):1414-1421.



31. Royle JA, Baade PD, Joske D, et al. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. *Br J Cancer*. 2011;105(7):1076-1081.
32. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. *Blood*. 2016;127(2):208-215.
33. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med*. 2015;373(25):2425-2437.
34. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. *N Engl J Med*. 2019;381(5):432-443.
35. Woyach JA, Ruppert AS, Mandrekar SJ. Ibrutinib regimens in older patients with untreated CLL: reply. *N Engl J Med*. 2019;380(17):1680-1681.
36. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019;20(1):43-56.
37. Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. *Lancet Oncol*. 2015;16(2):169-176.
38. Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. *Blood*. 2018;131(21):2357-2366.
39. Oscier DG, Wade R, Orchard J, et al. Prognostic factors in the UK LRF CLL4 trial. *Blood*. 2006;108(11):299.
40. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. *Lancet*. 2007;370(9583):230-239.
41. Strati P, Keating MJ, O'Brien SM, et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. *Haematologica*. 2014;99(8):1350-1355.
42. Fabbri G, Khiabani H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. *J Exp Med*. 2013;210(11):2273-2288.
43. Tam CS, Opat S, Zhu J, et al. Pooled analysis of safety data from monotherapy studies of the Bruton tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111) in B-cell malignancies. Presented at: 24th European Hematology Association Congress; June 13-16, 2019; Amsterdam, The Netherlands.
44. Hillmen P, Brown JR, Eichhorst BF, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. *Future Oncol*. 2020;16(10):517-523.

45. Tam CS, LeBlond V, Novotny W, et al. A head-to-head phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. *Future Oncol.* 2018;14(22):2229-2237.
46. Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. *N Engl J Med.* 2019;380(22):2095-2103.
47. Lampson BL, Tyekucheva S, Crombie JL, et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL). *Blood.* 2019;134(Suppl 1):32.

**Table 1.** Key patient and disease characteristics

	<b>TN del(17p) CLL/SLL (n = 109)</b>
Follow-up, median (range), mo	18.2 (5.0 – 26.3)
<b>Demographics</b>	
Age, median (range), y	70.0 (42 – 86)
Male sex, n (%)	78 (71.6)
ECOG PS of 2, n (%)	14 (12.8)
Months since diagnosis, median (Q1 - Q3)	21.6 (7.7 – 54.8)
<b>Disease Characteristics</b>	
SLL, n (%)	10 (9.2)
Binet stage C for patients with CLL, n (%)	40/99 (40.4)
ALC (x 10 <sup>9</sup> /L), median	65.1
Hemoglobin (g/L), median	120.0
Platelet count (x 10 <sup>9</sup> /L), median	154.0
β2-microglobulin <sup>a</sup> > 3.5 g/dL, n (%)	78/99 (78.8)
IGHV mutational status, <sup>b</sup> n (%)	
Mutated	36/103 (35.0)
Unmutated	67/103 (65.0)
Bulky disease, <sup>c</sup> n (%)	
Any TL LDi ≥ 5 cm	42 (38.5)
Any TL LDi ≥ 10 cm	11 (10.1)
Cytopenia present, <sup>d</sup> n (%)	61 (56.0)
Proportion of cells with del(17p), n (%)	
7.5% – 10%	16 (14.7)
10.5% – 20.0%	44 (40.4)
20.5% – 50.0%	13 (11.9)
50.5% – 100%	36 (33.0)
Mean % (SD)	36.0 (31.6)
Karyotype status, <sup>e</sup> n (%)	
Non-Complex (0 to 2 abnormalities)	54/86 (62.8)
Complex	
3 or more abnormalities	32/86 (37.2)
5 or more abnormalities	23/86 (26.7)

AE, adverse event; ALC, absolute lymphocyte count; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy chain variable; LDi, longest diameter; SD, standard deviation; SLL, small lymphocytic lymphoma; TL, target lesion; TN, treatment naïve.

<sup>a</sup>10 patients had missing data.

<sup>b</sup>Six patients had RNA quantity/quality not sufficient for polymerase chain reaction (PCR) amplification of heavy-chain variable (VH) region for sequencing.

<sup>c</sup>Patients with any target lesion with longest diameter presented.

<sup>d</sup>Patients having anemia ( $\leq 110$  g/L), thrombocytopenia ( $\leq 100 \times 10^9/L$ ), or neutropenia ( $\leq 1.5 \times 10^9/L$ ).

<sup>e</sup>23 patients had insufficient metaphases available for analysis.

**Table 2.** Summary of investigator-assessed efficacy

<b>Efficacy Variable</b>	<b>TN del(17p) CLL/SLL (n = 109)</b>
<b>Best response, n (%)</b>	
ORR (CR, PR, or PR-L), n (%) [95% CI] <sup>a</sup>	103 (94.5) [88 – 98]
CR	3 (2.8)
CRi	1 (0.9)
PR	95 (87.2)
PR-L	4 (3.7)
SD	5 (4.6)
PD	1 (0.9)
<b>Time to response, mo</b>	
PR-L or higher, median (range)	2.79 (1.9 – 16.5)
PR or higher, median (range)	2.89 (1.9 – 16.5)
<b>DOR</b>	
Response ≥ 12 mo, % [95% CI] <sup>a</sup>	92.8 [85.4 – 96.5]
<b>Estimated PFS rate, %</b>	
12 months [95% CI] <sup>a</sup>	94.5 [88.2 – 97.5]
18 months [95% CI] <sup>a</sup>	88.6 [79.0 – 94.0]

CI, confidence interval; CLL, chronic lymphocytic leukemia; CR, complete response; DOR, duration of response; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; PR-L, PR with lymphocytosis; SD, stable disease; SLL, small lymphocytic lymphoma; TN, treatment naïve.

<sup>a</sup>Two-sided Clopper-Pearson 95% CIs.

**Table 3.** Most common AEs regardless of causality. AEs of any grade occurring in  $\geq 5\%$  of patients and all grade  $\geq 3$  adverse events occurring in  $\geq 2\%$  of patients are shown.<sup>a</sup>

Term	Any Grade	Grade 1/2	Grade 3 n (%)	Grade 4	Grade 5
Patients with at least 1 AE	<b>106 (97.2)</b>	<b>53 (48.6)</b>	<b>44 (40.4)</b>	<b>7 (6.4)</b>	<b>2 (1.8)</b>
<b>Hematologic AEs</b>					
Neutropenia	13 (11.9)	3 (2.8)	7 (6.4)	3 (2.8)	0 (0)
Neutrophil count decreased	6 (5.5)	2 (1.8)	1 (0.9)	3 (2.8)	0 (0)
<b>Nonhematologic AEs</b>					
Contusion	22 (20.2)	22 (20.1)	0 (0)	0 (0)	0 (0)
Upper respiratory tract infection	21 (19.3)	21 (19.3)	0 (0)	0 (0)	0 (0)
Diarrhea	18 (16.5)	17 (15.6)	1 (0.9)	0 (0)	0 (0)
Nausea	16 (14.7)	16 (14.7)	0 (0)	0 (0)	0 (0)
Constipation	15 (13.8)	15 (13.8)	0 (0)	0 (0)	0 (0)
Rash	15 (13.8)	15 (13.8)	0 (0)	0 (0)	0 (0)
Back pain	14 (12.8)	13 (11.9)	1 (0.9)	0 (0)	0 (0)
Cough	13 (11.9)	13 (11.9)	0 (0)	0 (0)	0 (0)
Arthralgia	12 (11.0)	12 (11.0)	0 (0)	0 (0)	0 (0)
Fatigue	11 (10.1)	10 (9.2)	1 (0.9)	0 (0)	0 (0)
Dyspepsia	10 (9.2)	10 (9.2)	0 (0)	0 (0)	0 (0)
Headache	9 (8.3)	8 (7.3)	1 (0.9)	0 (0)	0 (0)
Fall	9 (8.3)	7 (6.4)	2 (1.8)	0 (0)	0 (0)
Pain in extremity	9 (8.3)	8 (7.3)	1 (0.9)	0 (0)	0 (0)
Pneumonia	9 (8.3)	5 (4.6)	3 (2.8)	0 (0)	1 (0.9)
Abdominal pain	8 (7.3)	8 (7.3)	0 (0)	0 (0)	0 (0)
Dyspnea	8 (7.3)	8 (7.3)	0 (0)	0 (0)	0 (0)
Epistaxis	8 (7.3)	7 (6.4)	1 (0.9)	0 (0)	0 (0)
Hematuria	8 (7.3)	6 (5.5)	2 (1.8)	0 (0)	0 (0)
Nasopharyngitis	8 (7.3)	8 (7.3)	0 (0)	0 (0)	0 (0)
Pruritus	8 (7.3)	8 (7.3)	0 (0)	0 (0)	0 (0)
Pyrexia	8 (7.3)	7 (6.4)	1 (0.9)	0 (0)	0 (0)
Hypertension	7 (6.4)	5 (4.6)	2 (1.8)	0 (0)	0 (0)
Muscle spasms	7 (6.4)	7 (6.4)	0 (0)	0 (0)	0 (0)
Urinary tract infection	7 (6.4)	5 (4.6)	2 (1.8)	0 (0)	0 (0)
Vomiting	7 (6.4)	7 (6.4)	0 (0)	0 (0)	0 (0)
Hematoma	6 (5.5)	6 (5.5)	0 (0)	0 (0)	0 (0)
Musculoskeletal pain	6 (5.5)	5 (4.6)	1 (0.9)	0 (0)	0 (0)
Skin laceration	6 (5.5)	6 (5.5)	0 (0)	0 (0)	0 (0)

AE, adverse event.

<sup>a</sup>Data are for treatment-emergent adverse events in the 109 patients in this arm of the study.

## FIGURE LEGENDS

**Figure 1.** Survival and response analyses using the Kaplan-Meier method. **A.** Progression-free survival as determined by investigator assessment. Shaded area indicates 95% CI. **B.** Overall survival. Shaded area indicates 95% CI. **C.** Duration of response as determined by investigator assessment. Shaded area indicates 95% CI.

**Figure 2.** Subgroup analysis of overall response rate. Overall response rate presented as of November 1, 2019. Two-sided Clopper-Pearson 95% CIs are used. CLL, chronic lymphocytic lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; LDi, longest diameter; SLL, small lymphocytic leukemia.




<sup>a</sup>Patients with any target lesion with longest diameter presented.


<sup>b</sup>Six patients had RNA quantity/quality not sufficient for PCR amplification of VH region for sequencing.

<sup>c</sup>Patients having anemia ( $\leq 110$  g/L), thrombocytopenia ( $\leq 100 \times 10^9/L$ ), or neutropenia ( $\leq 1.5 \times 10^9/L$ ).

<sup>d</sup>10 patients had missing data.

<sup>e</sup>23 patients had insufficient metaphases available for analysis.







## SUPPLEMENTAL MATERIAL

**Supplemental Table 1:** Adverse Events of Interest: Categories and Corresponding Search Criteria

<b>AEI Category</b>	<b>Search Criteria</b>
Bruising	Purpura PT, contusion PT, ecchymosis PT, increased tendency to bruise PT
Major bleeding	<ul style="list-style-type: none"> <li>• Subdural hematoma PT or subdural hemorrhage PT</li> <li>• All hemorrhage PTs if AE SOC is “nervous system disorders”</li> <li>• Any serious or grade <math>\geq 3</math> hemorrhage PT if AE SOC is not “nervous system disorders”</li> </ul>
Minor bleeding	Hemorrhage terms (excluding laboratory terms) (SMQ) Narrow, except for PTs in Bruising category, Major bleeding category, and petechiae
Atrial fibrillation and flutter	Atrial fibrillation PT, atrial flutter PT
Hypertension	Hypertension (SMQ) Narrow
Other malignancies Skin cancers	Malignant Tumors (SMQ) Narrow Subcategory - skin cancers: skin malignant tumors (SMQ) Narrow
Infection Pneumonia Opportunistic infections	Infections: Infections and infestations SOC Subcategory – Pneumonia (SMQ) Narrow Subcategory – Opportunistic infections (SMQ) Narrow
Neutropenia	Neutropenia PT, neutrophil count decreased PT, febrile neutropenia PT, agranulocytosis PT, neutropenic infection PT, neutropenic sepsis PT
Thrombocytopenia	Thrombocytopenia PT, platelet count decreased PT
Anemia	Anemia PT, hemoglobin decreased PT
Diarrhea	Diarrhea PT, diarrhea infectious PT, <i>Clostridium difficile</i> colitis PT, diarrhea hemorrhagic PT

AEI, adverse event of interest; CMQ, Company MedDRA Query; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; SMQ, Standardized MedDRA Query; SOC, system organ class.

**Supplemental Table 2.** Listing of Sites and Investigators by Number of Patients Enrolled

Site	PI	Country	Patients Enrolled
Peninsula Private Hospital	Walker, Patricia	Australia	6
St Vincent's Hospital	Tam, Constantine	Australia	6
Calvary Mater Hospital	Janowski, Wojciech	Australia	5
North Shore Hospital	Simpson, David	New Zealand	5
Fred Hutchinson Cancer Research Center	Shadman, Mazyar	United States	4
Peter MacCallum Cancer Centre	Tam, Constantine	Australia	4
AUSL Ravenna	Tani, Monica	Italy	3
Christchurch Hospital/Canterbury Health	Ganly, Peter	New Zealand	3
Concord Hospital	Verner, Emma	Australia	3
Copernicus Podmiot Leczniczy Sp. z o.o. Wojewódzkie Centrum Onkologii	Ciepluch, Hanna	Poland	3
Dana Farber Cancer Institute	Brown, Jennifer	United States	3
Monash Health	Opat, Stephen	Australia	3
Universitario Agostino Gemelli	Laurenti, Luca	Italy	3
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda	Tedeschi, Alessandra	Italy	2
University Hospital Hradec Kralove	Simkovic, Martin	Czech Republic	2
Russian Research Institute of Hematology and Transfusiology	Voloshin, Sergey	Russia	2
Karolinska Universitetssjukhuset	Osterborg, Anders	Sweden	2
Ordensklinikum Linz GmbH	Petzer, Andreas	Austria	2
Palmerston North Hospital	Baker, Bartrum	New Zealand	2
Royal Hobart Hospital	Harrup, Rosemary	Australia	2
Sahlgrenska University Hospital	Lewerin, Catharina	Sweden	2
Tauranga Hospital	Corbett, Gillian	New Zealand	2
Leeds Teaching Hospitals	Hillmen, Peter	United Kingdom	2
Uppsala University Hospital	Mattsson, Mattias	Sweden	2
Vseobecna fakultni nemocnice v Praze	Trneny, Marek	Czech Republic	2
University Hospital Southampton	Forconi, Francesco	United Kingdom	1
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Motta, Marina	Italy	1
Box Hill Hospital	Ting, Stephen	Australia	1
Cambridge Hospitals	Follows, George	United Kingdom	1
Centre Henri-Becquerel	Lepretre, Stephane	France	1
Centre Hospitalier Le Mans	Laribi, Kamel	France	1
Clinique Saint-Pierre	Connerotte, Thierry	Belgium	1
Fakultní nemocnice Olomouc	Papajik, Tomas	Czech Republic	1

N.N. Blokhin National Medical Research Center for Oncology	Tumyan, Gayane	Russia	1
Hopital Pontchaillou CHU	De Guibert, Sophie	France	1
Hospitalier du Haut Leveque	Dilhuydy, Marie-Sarah	France	1
Insitut d'Hématologie de Basse Normandie	Vilque, Jean-Pierre	France	1
Joe Arrington Cancer Research and Treatment Center	Quick, Donald	United States	1
Kent and Canterbury Hospital	Young, Moya	United Kingdom	1
Landeskrankenhaus Salzburg	Greil, Richard	Austria	1
Malopolskie Centrum Medyczne S.C.	Jurczak, Wojciech	Poland	1
Medizinische Universitaetsklinik Innsbruck	Wolf, Dominik	Austria	1
Mount Sinai School of Medicine	Shulman, Jonah	United States	1
National Taiwan University Hospital	Cheng, Chieh-Lung	Chinese Taipei	1
The Tweed Hospital	Sia, Hanlon	Australia	1
Oregon Health and Science University	Danilov, Alexei	United States	1
Ospedale San Raffaele	Ghia, Paolo	Italy	1
Plymouth Hospitals	Hutchinson, Claire	United Kingdom	1
Princess Alexandra Hospital	Marlton, Paula	Australia	1
Regional Clinical Hospital	Pristupa, Alexander	Russia	1
Royal Brisbane and Women's Hospital	Weber, Nicholas	Australia	1
Skånes Universitetssjukhus	Juliusson, Gunnar	Sweden	1
Sunderby Sjukhus	Lauri, Birgitta	Sweden	1
Sverdlovsk Regional Clinical Hospital # 1	Konstantinova, Tatiana	Russia	1
Tennessee Oncology	Flinn, Ian	United States	1
The Royal Marsden	Iyengar, Sunil	United Kingdom	1
Tula Regional Clinical Hospital	Volodicheva, Elena	Russia	1
University of Virginia Health System	Portell, Craig	United States	1
Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi	Robak, Tadeusz	Poland	1

### Supplemental Table 3. Sustained Hematologic Improvement

Sustained Improvements by Laboratory Parameter, n (%) <sup>a</sup>	
Absolute Neutrophil Count <sup>b</sup>	6/8 (75.0)
Hemoglobin <sup>c</sup>	37/43 (86.0)
Platelet count <sup>d</sup>	24/28 (85.7)

<sup>a</sup>Percentages calculated as percent of patients with the particular cytopenia at baseline. Cytopenia was defined as follows: anemia ( $\leq 110$  g/L), thrombocytopenia ( $\leq 100 \times 10^9/L$ ), or neutropenia ( $\leq 1.5 \times 10^9/L$ ).

<sup>b</sup>Sustained improvement in absolute neutrophil count is defined as an increase to at least  $1.5 \times 10^9/L$  or increase of at least 50% over baseline, maintained for at least 56 days without growth factors during this period.

<sup>c</sup>Sustained improvement in hemoglobin defined as an increase of 20 g/L over baseline and maintained for at least 56 days without blood transfusion or growth factors during this period.

<sup>d</sup>Sustained improvement in platelet count is defined an increase to at least  $100 \times 10^9/L$  or an increase of at least 50% over baseline, maintained for at least 56 days without blood transfusion or growth factors during this period.

**Supplemental Table 4.** Disease Characteristics and Best Overall Response by del(17p) Frequency

Patients, n (%)	del(17p) Result > 7% - < 20%	del(17p) Result ≥ 20%
	59/109 (54.1)	50/109 (45.9)
<b>Disease Characteristics</b>		
Age, median (range), y	70.0 (42 – 84)	70.0 (45 – 86)
ECOG PS of 2, n (%)	6 (10.2)	8 (16)
Months since diagnosis, median (Q1 - Q3)	24.28 (8.28 – 51.22)	17.12 (5.39 – 56.21)
Binet stage C for patients with CLL, n (%)	20 (37.0)	20 (44.4)
β2-microglobulin <sup>a</sup> > 3.5 g/dL, n (%)	42/55 (76.3)	36/44 (81.8)
IGHV mutational <sup>b</sup> status		
Mutated	24/55 (43.6)	12/48 (25.0)
Unmutated <sup>c</sup>	31/55 (56.4)	36/48 (75.0)
Bulky disease <sup>d</sup> , n (%)		
Any TL LDi ≥ 5 cm	27 (45.8)	15 (30.0)
Any TL LDi ≥ 10 cm	6 (10.2)	5 (10.0)
Cytopenia present, <sup>e</sup> n (%)	34 (57.6)	27 (54.0)
Karyotype status, <sup>f</sup> n (%)		
Non-Complex (0 to 2 abnormalities)	38/49 (77.6)	16/37 (43.2)
Complex (3 or more abnormalities)	11/49 (22.4)	21/37 (56.8)
<b>Best response, n (%)</b>		
ORR (CR, PR, or PR-L), n (%) [95% CI] <sup>g</sup>	54 (92) [81 – 97]	49 (98) [89 – 100]
CR/CRi	1/59 (1.7)	3/50 (6.0)
PR	51/59 (86.4)	44/50 (88.0)
PR-L	2/59 (3.4)	2/50 (4.0)
SD	4/59 (6.8)	1/50 (2.0)
PD	1/59 (1.7)	0/50 (0.0)
Estimated 12-month PFS, % [95% CI] <sup>g</sup>	95 [85 – 98]	94 [83 – 98]
Estimated 18-month PFS, % [95% CI] <sup>g</sup>	88 [72 – 95]	89 [76 – 95]

CI, confidence interval; CLL, chronic lymphocytic leukemia; CR, complete response; CRi, complete response with incomplete hematologic recovery; ECOG PS, Eastern Cooperative Oncology Group performance status; LDi, longest diameter; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; PR-L, PR with lymphocytosis; SD, stable disease; TL, target lesion.

<sup>a</sup>10 patients had missing data.

<sup>b</sup>RNA quantity/quality not sufficient for PCR amplification of VH region for sequencing.

<sup>c</sup>Chi-square test for statistical significance;  $P = 0.0478$ .

<sup>d</sup>Patients with any target lesion with longest diameter presented.

<sup>e</sup>Patients with anemia ( $\leq 110$  g/L), thrombocytopenia ( $\leq 100 \times 10^9/L$ ), or neutropenia ( $\leq 1.5 \times 10^9/L$ )

<sup>f</sup>10 and 13 patients had insufficient metaphases available for analysis in the del(17p) result >7%-< 20% and del(17p) result  $\geq 20\%$  categories, respectively.

<sup>g</sup>Two-sided Clopper-Pearson 95% CIs.

**Supplemental Table 5. Adverse Events of Interest Grouped by Category**

Category	Grade 1/2	Grade 3 or Higher	All Grades
	n (%)		
<b>Hematologic</b>			
Neutropenia	5 (4.6)	15 (13.8)	20 (18.3)
Thrombocytopenia	6 (5.5)	1 (0.9)	7 (6.4)
Anemia	4 (3.7)	0 (0)	4 (3.7)
<b>Nonhematologic</b>			
Infections	55 (50.5)	15 (13.8)	70 (64.2)
Minor Bleeding	29 (26.6)	0 (0)	29 (26.6)
Bruising	27 (24.8)	0 (0)	27 (24.8)
Diarrhea	16 (14.7)	1 (0.9)	17 (15.6)
Nausea	15 (13.8)	0 (0)	15 (13.8)
Arthralgia	12 (11.0)	0 (0)	12 (11.0)
Fatigue	10 (9.2)	1 (0.9)	11 (10.1)
Dermatologic malignancies	8 (7.3)	2 (1.8)	10 (9.2)
Headache	8 (7.3)	1 (0.9)	9 (8.3)
Hypertension	6 (5.5)	3 (2.8)	9 (8.3)
Major bleeding	1 (0.9)	5 (4.6)	6 (5.5)
Other non-dermatologic malignancies	0 (0)	5 (4.6)	5 (4.6)
Myalgia	4 (3.7)	1 (0.9)	5 (4.6)
Atrial fibrillation and flutter	1 (0.9)	2 (1.8)	3 (2.8)


**Supplemental Table 6.** Description of Major Bleeding Adverse Events

Patient Characteristics	Adverse Event and CTCAE Toxicity Grade	Study Day Start and End of AE	SAE?	AE Relationship per Investigator	Confounding Factors
78 years Male	Pericholecystic hematoma, grade 3	292 – 295	Yes	Not related	Occurred in the setting of cholecystitis and coadministration of apixaban and heparin for 4 days prior to event given for atrial fibrillation. Last dose of study drug prior to event was given on study day 277.
72 years Female	Postoperative hemorrhage, grade 3	334 – 345	Yes	Not related	Occurred in the setting of removal of a melanoma lesion of the skin. Study drug was not held until day of event.
42 years Male	Epistaxis, grade 3	2 – 4	Yes	Not related	
78 years Male	Purpura, grade 1	16 – 43	Yes	Related	Occurred in the setting of mechanical fall and resultant hospitalization. AE was deemed serious due to hospitalization. Patient was on concurrent aspirin at time of event.
73 years Male	Macrohematuria, grade 3	201 – 201	No	Not related	Occurred in the setting of a transurethral resection of prostate gland. Study drug was not held until day of event. Patient was on concurrent aspirin at time of event.
72 years Male	Haematuria, grade 3	107 – 121	No	Not related	


AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; SAE, serious AE.

### Supplemental Figure 1.

**A.** Change in ALC and SPD over time with zanubrutinib treatment. Graph plotted as median change from baseline ALC in red and baseline SPD in blue. Data points represent all data collected during the treatment cycle of 28 days. Bars represent 1 standard deviation; numbers represent individual patient data generated during each timepoint.



**B.** Effect of IGHV status on change in ALC over time with zanubrutinib treatment. Graph plotted as median change from baseline ALC of patients with IGHV mutated status in blue and IGHV unmutated status in red. Data points represent all data collected during the treatment cycle of 28 days. Bars represent 1 standard deviation; numbers represent individual patient data generated during each timepoint.



ALC, absolute lymphocyte count; SPD, sum of the products of lymph node diameters.